William Lumry
A5090720454- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hemophilia Treatment and Research
- Asthma and respiratory diseases
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Allergic Rhinitis and Sensitization
- Vitamin K Research Studies
- Respiratory and Cough-Related Research
- Mast cells and histamine
- PI3K/AKT/mTOR signaling in cancer
- Inhalation and Respiratory Drug Delivery
- Immunodeficiency and Autoimmune Disorders
- Enzyme function and inhibition
- Chronic Myeloid Leukemia Treatments
- Drug-Induced Adverse Reactions
- Peptidase Inhibition and Analysis
- Pharmaceutical studies and practices
- Blood disorders and treatments
- Olfactory and Sensory Function Studies
- Beetle Biology and Toxicology Studies
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Sinusitis and nasal conditions
- Inflammatory mediators and NSAID effects
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Allergy Associates Research Center
2015-2025
Asthma and Allergy Specialists
2014-2024
Ionis Pharmaceuticals (United States)
2024
Asthma Association
2014-2024
Charité - Universitätsmedizin Berlin
2024
Humboldt-Universität zu Berlin
2024
Goethe University Frankfurt
2024
University Hospital Frankfurt
2024
Semmelweis University
2024
Associates Research
1999-2023
Hereditary angioedema is characterized by recurrent attacks of the skin, larynx, and gastrointestinal tract. Bradykinin key mediator symptoms. Icatibant a selective bradykinin B2 receptor antagonist.
Abstract Hereditary Angioedema ( HAE ) is a rare and disabling disease. Early diagnosis appropriate therapy are essential. This update revision of the global guideline for provides up‐to‐date consensus recommendations management . In development this guideline, an international expert panel reviewed existing evidence developed 20 that were discussed, finalized consented during conference in June 2016 Vienna. The final version incorporates contributions board reviewers endorsing societies....
Hereditary angioedema due to C1 inhibitor deficiency is characterized by recurrent acute attacks of swelling that can be painful and sometimes life-threatening.
Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis appropriate therapy are often unknown or not available physicians other health care providers. For we convened group of specialists that focus upon HAE from around the world to develop only consensus on management HAE, but also provide evidence based grades, strength classification consensus. Since both grading were adhered document meets criteria as guideline. The outcome guideline improve patients with...
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis effective therapy are critical. This revision update of the global WAO/EAACI guideline on management HAE provides up-to-date guidance HAE. For this guideline, an international panel experts reviewed existing evidence, developed 28 recommendations, established consensus by online DELPHI process. The goal these recommendations to help physicians their patients in making rational decisions with deficient C1...
Hereditary angioedema (HAE) is a rare, autosomal dominant disorder characterized by recurrent acute attacks of swelling the larynx, abdomen, and periphery. This study was designed to assess humanistic burden illness associated with HAE. HAE assessed via web-based survey patients that solicited information on attack characterization, treatment, side effects, pain, functional emotional disease management. In addition HAE-specific sections, used three standardized instruments compare patient...
Scientific and clinical progress together with the development of effective novel therapeutic options has engendered multiple important changes in diagnosis management hereditary angioedema (HAE). We now update extend 2013 United States Hereditary Angioedema Association Medical Advisory Board guidelines for treatment HAE. The are based on a comprehensive literature review recommendations indicating both strength our recommendation quality underlying evidence. Guidelines provided regarding...
Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, preventing attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites Canada, Europe, Jordan, and United States. Patients were randomized between March 2016, September 9, 2016; last day follow-up was April 13, 2017. Randomization 2:1...
Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction II) of the C1 inhibitor protein. In phase 2 trial, use CSL830, nanofiltered preparation that suitable for subcutaneous injection, resulted in functional levels activity would be expected to provide effective prophylaxis attacks.We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 3 trial evaluate efficacy and safety...
Leukotriene antagonists block the proinflammatory actions of leukotrienes (LT) and have been introduced as new treatments for asthma. Conventional therapy with glucocorticosteroids does not inhibit biosynthesis leukotrienes. We therefore tested whether addition leukotriene receptor antagonist montelukast was therapeutic benefit in a group aspirin-intolerant patients asthma whom 90% already were treated moderate to high doses glucocorticosteroids. Under double-blind conditions, 80 randomized...
Three hundred forty-nine patients with asthma previously treated medium doses of inhaled corticosteroids during a 2-wk, single-blind, run-in period were randomized to treatment salmeterol 50 μ g combined fluticasone propionate (FP) 250 g, FP or placebo, each given twice daily through Diskus device for 12 wk. Mean change in FEV1 at endpoint was significantly (p ⩽ 0.001) greater the salmeterol/FP combination product (0.48 L) than placebo ( − 0.11 L), (0.05 (0.25 L). The increased area under...
Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpredictable swelling episodes caused uncontrolled plasma kallikrein generation and excessive bradykinin release resulting from cleavage of high-molecular-weight kininogen. Lanadelumab (DX-2930) a new the potential for prophylactic treatment hereditary deficiency.We conducted phase 1b, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial. Patients were randomly assigned in 2:1 ratio to...
Despite its relatively common occurrence and life-threatening potential, the management of angioedema in emergency department (ED) is lacking terms a structured approach. It paramount to distinguish different etiologies from one another more specifically differentiate histaminergic-mediated bradykinin-mediated angioedema, especially lieu novel treatments that have recently become available for angioedema. With this background mind, consensus parameter evaluation attempts provide working...